Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation 　- The Prospective KYU-RABLE Study.

CONCLUSIONS: The present study provided evidence of the efficacy and safety of uninterrupted edoxaban administered once daily in the morning, with one dose delayed on procedural day, in patients with AF undergoing CA. Edoxaban was associated with a low risk of periprocedural thromboembolic and bleeding complications. PMID: 31511436 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31511436?dopt=Abstract

Source: Circulation Journal - September 11, 2019 Category: Cardiology Authors: Takahashi N, Mukai Y, Kimura T, Yamaguchi K, Matsumoto T, Origasa H, Okumura K, KYU-RABLE Investigators Tags: Circ J Source Type: research

Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation - The Prospective KYU-RABLE Study.

Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation 　- The Prospective KYU-RABLE Study.